Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
Clinical Pharmacology & Therapeutics2016Vol. 101(6), pp. 721–724
Citations Over TimeTop 10% of 2016 papers
XS Xu, Xiaoyu Yan, Thomas A. Puchalski, Sagar Lonial, HM Lokhorst, PM Voorhees, Trine Lindhardt Plesner, Kui Liu, Imran Khan, R Jansson, Tahamtan Ahmadi, Juan José Pérez Ruixo, Honghui Zhou, Pamela L. Clemens
Abstract
New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first-in-class, CD38 human immunoglobulin G1κ monoclonal antibody approved for treatment of relapsed or refractory MM. Identification of an appropriate dose regimen for daratumumab is challenging due to its target-mediated drug disposition, leading to time- and concentration-dependent pharmacokinetics. We describe a thorough evaluation of the recommended dose regimen for daratumumab in patients with relapsed or refractory MM.
Related Papers
- → Daratumumab: A review of current indications and future directions(2022)27 cited
- → Potential role of daratumumab in the treatment of multiple myeloma(2014)34 cited
- → A Case of Panagglutination on Antibody Identification in a Multiple Myeloma Patient Receiving Daratumumab(2016)5 cited
- → Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Center Experience(2017)
- → Daratumumab(2021)